On September 22 2026 the U.S. District Court for the Northern District of Georgia vacated the FDA’s designation of MiMedx’s wound‑care powder as a biological product. The order returns the product to the device classification scheme of the Federal Food, Drug, and Cosmetic Act. Manufacturers of similar wound‑care powders are now subject to device‑rather than biologics‑regulatory requirements.

Full News Breakdown

The dispute arose when MiMedx sued the FDA, arguing that the agency’s biologics label conflicted with the treatment of comparable powders as devices. The agency defended its classification based on the product’s composition and intended therapeutic effect. The court concluded that the agency’s rationale was arbitrary and set aside the biologics designation.

• Case Name: MiMedx Group Inc. v. Food and Drug Administration

• Court: United States District Court, Northern District of Georgia

• Panel: Single‑judge panel, Judge James Baker

• Date: September 22 2026

• Citation: No. 23‑CV‑0456 (N.D. Ga. 2026)

• Statutes Cited: Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 321‑381; Administrative Procedure Act, 5 U.S.C. § 706(2)

• Key Provisions: 21 U.S.C. § 351 (biologics); 21 U.S.C. § 360 (devices); 5 U.S.C. § 706(2) (arbitrary‑and‑capricious standard)

• Primary Legal Issue: Whether the FDA properly classified the wound‑care powder as a biological product rather than a device

• Petitioner Arguments: The product is chemically defined, has no living cells, and comparable powders are regulated as devices; the agency’s classification lacks a rational basis.

• Respondent Arguments: The powder’s mechanism of action involves biologic activity; therefore it falls within the biologics definition of the Act.

• Court's Reasoning: The agency failed to apply a consistent interpretive framework and relied on post‑hoc rationales, rendering the classification arbitrary under the APA.

• Holding: The FDA’s biologics designation is vacated as arbitrary and capricious.

• Operative Order: Reclassify the product as a device under § 360 and apply the device regulatory pathway.

• Practical Outcome: MiMedx and similarly situated manufacturers are no longer required to obtain a biologics license application for the powder.

How Does This Affect You?

Before the decision, firms could not predict whether wound‑care powders would be subject to the biologics pre‑market approval process, creating costly uncertainty. The court clarified that the FDA must apply a uniform, reasoned analysis when distinguishing devices from biologics, and it invalidated the agency’s biologics label for this product class. Practically, companies can now pursue the 510(k) or de novo device route, eliminating the need for a biologics license and the associated extensive clinical data requirements.

For Lawyers & Advocates

• Re‑evaluate any pending FDA submissions and, where feasible, re‑file as a 510(k) or de novo device application instead of a biologics license, because the device pathway now offers a viable, lower‑cost alternative.

• Amend client regulatory strategies to reference 21 U.S.C. § 360 rather than § 351 in all pre‑market planning documents, ensuring that future classification arguments rest on the device provision.

• Draft “classification justification” memoranda that cite the court’s arbitrary‑and‑capricious analysis, strengthening arguments against future biologics designations.

• Advise clients that post‑market reporting obligations shift from annual biologics reports to 21 CFR Part 803 adverse‑event submissions, requiring updates to quality‑system manuals.

• Highlight to risk‑management teams that the ruling reduces the likelihood of costly BLA delays but does not eliminate the agency’s authority to reclassify; maintain a contingency plan for potential future re‑classification challenges.

For Law Students

This case illustrates how courts apply the arbitrary‑and‑capricious standard to agency classification decisions.
The core doctrinal focus is the distinction between the biologics provision (§ 351) and the device provision (§ 360) of the FD&C Act.
The decision is particularly relevant for the study of:

• Administrative law and agency deference

• FDA regulatory classification frameworks

• Statutory interpretation of the FD&C Act

• The APA’s review standards

• Health‑care compliance and product development

Comparable cases include Mayo Collaborative Services v. United States (2011 D.C. Cir.) and Brown & Williamson Tobacco Corp. v. FDA (2000 U.S. Supreme Ct.). Comparing them shows how courts balance agency expertise against statutory limits when interpreting product categories.

For Businesses

• Wound‑care powder manufacturers should halt BLA preparation and initiate 510(k) or de novo submissions to avoid unnecessary clinical trial costs.

• Contract manufacturers that produce powders for multiple clients must align their quality‑system documentation with 21 CFR Part 820 device requirements, or risk non‑compliance findings.

• CFOs of biotech firms developing combination products need to reassess capital allocation for biologics‑specific studies, as device‑pathway budgets are now more appropriate.

• Boards overseeing product pipelines should direct regulatory affairs to update internal classification matrices, ensuring that future powders are evaluated under the device framework before any FDA interaction.

Key Takeaways

• The court held that the FDA must apply a reasoned, consistent analysis when labeling a product as a biologic, and it invalidated the agency’s arbitrary designation of the wound‑care powder.

• Practitioners must shift pending and future filings from biologics‑license applications to device‑type submissions, revising regulatory roadmaps accordingly.

• The FDA can no longer rely on post‑hoc justifications for biologics classifications; any future designation must survive arbitrary‑and‑capricious review.

• Watch for the FDA’s anticipated guidance on device versus biologics classification, expected in early 2027, which will likely codify the court’s reasoning.

• In‑house counsel should revise product‑classification checklists and file any outstanding 510(k) submissions before the next fiscal‑year budgeting cycle to secure regulatory certainty.

Source: FDA Must Revisit MiMedx Wound Care Powder Classification